Aarti Drugs Ltd.
MarketLine (a Datamonitor Company)
28 Aug 2013
Available for Immediate Download
Aarti Drugs Ltd. - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Aarti Drugs Ltd. required for business and competitor intelligence needs - Intelligence on Aarti Drugs Ltd.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Aarti Drugs Ltd., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Aarti Drugs (ADL) is an Indian pharmaceutical company that is engaged in the manufacturing of vitamins, anti-arthritis, anti-fungal, antibiotics, and angiotensin converting enzyme (ACE) inhibitors. The company also manufactures anti-diabetics, anti- cholinergic, sedatives and anti-depressant drugs. The company primarily operates in India, where it is headquartered in Mumbai. The company recorded revenues of INR8,248.4 million (approximately $151.9 million) in the fiscal year ended March 2012, an increase of 25.1% over 2011. The company's operating profit was INR939.2 million (approximately $17.3 million) in fiscal 2012, an increase of 71.1% over 2011. Its net profit was INR452.4 million (approximately $8.3 million) in fiscal 2012, as compared to the net profit of INR224.6 million (approximately $4.1 million) in 2011. Reasons to Purchase: - Gain understanding of Aarti Drugs Ltd. the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Aarti Drugs Ltd. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Aarti Drugs Ltd. your competitors' business structure, strategy and prospects